NuVasive Expands Complex Spine Portfolio with Global Launch of Reline 3D for Pediatric Deformity

June 18, 2020

NuVasive, Inc. today announced the expansion of its complex spine portfolio with the global commercial availability of Reline 3Dā„¢, a posterior fixation system for patients suffering from pediatric spinal deformities.

NuVasive describes the Reline 3D system as optimized for the treatment of adolescent idiopathic scoliosis (AIS), which involves intricate surgical techniques to address the three-dimensional deformity present in the spine.

The system unifies current deformity techniques involving multi-step, single-plane correction, into one holistic procedure enabling surgeons to overcome current inefficiencies in the operating room. Reline 3D is designed to provide simultaneous, three-dimensional deformity correction, through a simplified procedure, offering surgeons versatility without sacrificing a reproducible surgical experience.

“Prior to Reline 3D, my approach to treating three-dimensional spinal deformities in pediatrics was inefficient and required treating the coronal, sagittal, and axial planes separately,” said Dr. Robert Cho, chief of staff and pediatric orthopedic surgeon at Shriners for Children Medical Center in Pasadena, California. “Reline 3D allows me to simultaneously correct all three planes of the deformity at once, minimizing stress on the bone-screw interface and rod deformation, and maximizing my three-dimensional correction in patients with complex spinal curvatures.”

Reline 3D is an extension of NuVasive’s RelineĀ® system, the most comprehensive fixation portfolio in spine, including Reline Open, Reline MAS, Reline Trauma and Reline Small Stature. Since its commercial launch, NuVasive has continued to invest in the Reline system with increased capabilities and applications spanning from open to minimally invasive surgery, all designed to treat a vast array of spinal pathologies under one portfolio.

“Reline 3D represents a true procedural solution that increases efficiencies and supports a less invasive approach to addressing complex pathologies,” said Matt Link, president of NuVasive. “As an innovative leader in less invasive surgery, NuVasive is committed to providing industry-leading procedures and technologies that enable health systems and surgeons to provide the same standard of care while reducing operative time and length of stay in the hospital. With this launch of Reline 3D, we have expanded this commitment to the AIS patient population.”

Reline 3D is commercially available to patients within the United States and European markets, and is expected to launch in other countries next year.

“As a key pioneer in expanding the utility of NuVasive’s Reline portfolio to create the Reline 3D system, it excites me that this differentiated solution is now widely available to the global spinal deformity community,” said Mr. Stewart Tucker, orthopaedic surgeon at Great Ormond Street Hospital in London, England. “Reline 3D creates a streamlined solution for complex deformities and my peers in the European spinal community have converted to using it simply based on its correctional ability, efficiencies and versatile applications across pediatric and adult spinal deformities.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s TransposeĀ® RT cell therapy system.
The decision cancels each of the original claims of the '345 Patent and declares unpatentable each of Swift's proposed substitute claims. Amongst the prior art deemed by the USPTO to render the '345 Patent unpatentable is a patent application licensed to MolecuLight that lists MolecuLight's Founder, Dr. Ralph DaCosta, as the sole inventor.
It combines the convenience of the Kaleido insulin pump with two market-leading innovations designed by Diabeloop and Dexcom to create a Hybrid Closed Loop system for managing type 1 diabetes which is flexible, self-learning and easy to use.
SYNICEM spacers are antibiotic-loaded, preformed spacers which overcome the challenges of traditional intra-operative moulded and handmade spacers. They help support surgeons' revisions of the hip, knee and shoulder by preserving articular space and aiding the treatment of infection.
This article courtesy of infomeddnews.com delves into the critical steps for launching a successful medical startup, while also highlighting the importance of a strong visual identity, achievable through tools like online logo makers.

By using this website you agree to accept Medical Device News Magazine Privacy Policy